A number of investigators have reported finding tumour-associated antigens (TAA) on cells of patients with myeloblastic leukaemia. These antigens have been described as being a glycoprotein of 75-80K dalton mol. wt (Baker et al., unpublished data) , a glycoprotein of 400 K dalton mol. wt (Taub et al., 1978) , or cell stage dependent proteins of 86K dalton mol. wt, respectively (Mulder et al., 1981) .
In this laboratory, we have identified what appears to be a TAA on human acute myelogenous leukaemia (AML) cells. This material, when isolated on native polyacrylamide gels and used to raise a conventional antiserum in rabbits, demonstrated complete specificity for AML cell membrane extracts in the ELISA (Malcolm et al., 1982) . It did not react with equivalent preparations of either normal peripheral blood leucocytes (PBL) or cells of patients with lymphoproliferative disorders. Further studies using this antiserum in FACS IV analyses established that the antigen with which it reacted was on the surface of bone marrow AML cells, but did not react with surface antigens of normal bone marrow cells or those of patients with other disorders (Malcolm et al., 1982) . More recently (Malcolm et al., 1983) , in a more extensive study, we have confirmed the apparent specificity of this antiserum with both PBL and bone marrow cells from a larger patient group. The present report constitutes a preliminary characterization of this TAA.
In the original procedures used for the preparation of the antigen, extracts of cell membranes from AML patients were passed initially over an immunoadsorbent column containing antiserum raised in rabbits to a pool of normal PBL membrane extracts (anti-normal human). The "fall-through" material was then run on preparative non-reducing polyacrylamide gels and the unique bands were cut out and eluted.
These preparations were then used to immunize rabbits. In the original study, 3 unique bands of protein were isolated (Malcolm et al., 1982) . It was subsequently found that the rabbit antisera, raised to each of these bands, were totally cross-reactive, indicating that the individual bands probably represented aggregated forms of the same antigen. This was further verified when materials were run on reducing gels, and it was found that only one band (mol. wt -68K daltons) was observed under these conditions (data not shown).
In order to determine whether the same protein band was present in extracts of cells from a number of individual patients with myelogenous leukaemia, or if it was detectable in extracts of cells from patients with lymphoproliferative disorders, individual extracts were prepared as described previously (Malcolm et al., 1982) , absorbed over the "anti-normal human" immunoadsorbent and run on SDS-PAGE according to previously described procedures (Laemmli, 1970; Gold et al., 1976) . Preparations previously equilibrated with SDS and 2-ME, were applied to 7.5% polyacrylamide gels and electrophoresed at 70V for 5-6h. The results (Figure 1 ) indicate that the 68K dalton component is present in all cell extracts from AML patients but is not detectable in extracts from other patient groups. These findings were not surprising in the light of previous observations that antisera raised against gel-purified AML proteins reacted only with either extracts or cells from patients with myelogenous leukaemias (Malcolm et al., 1982 (Malcolm et al., , 1983 .
Preparative reducing gels of absorbed AML cell extracts were run, and sufficient antigen eluted and concentrated from a number of individual patient samples so that they could be tested in 2dimensional gels to assess their purity, using the procedures of O'Farrell (1975) . Gels were developed using the silver stain (Wray et al., 1981) . The results (Figure 2) show that the AML antigen is composed of a major protein component of -68K daltons mol. wt with a pl between 7.1 and 7.2. The "tailing" seen is possibly due to differential glycosylation of the material. It should be noted that the bands of material (between 50-60 K daltons mol. wt) visible on the gel represent artifacts of the silver staining procedure. They appear consistently in all gels, even those which are run with no protein samples. When 1251-labelled AML antigen was run on 2D gels, these bands are not seen; however, some breakdown of the antigen itself was seen, presumably due to oxidation (Figure 3) . We were interested to establish whether the purified AML antigen was capable of blocking the ability of the anti-AML-antiserum described earlier (Malcolm et al., 1982) to bind the HL-60 human cell line (derived from a promyelocytic leukaemia, and obtained from Dr. R.C. Gallo, N.C.I., Bethesda, Md.). An inhibition assay was performed, in which either normal human membrane antigens or the AML antigen (both at concentrations of 40pg ml-') were preincubated with either normal rabbit serum (NRS), rabbit antiserum to normal human PBL membrane antigens, or to the purified AML antigen. Antisera were then reacted with HL-60 cells for subsequent FACS IV analysis as described previously (Malcolm et al., 1982) . The results (Table  I) show clearly that the AML antigen successfully blocks the reaction of the specific anti-AML antiserum with HL-60 but has no effect on the pH 6.4 Table I Results of FACS IV analysis of HL-60 cells with sera (1: 10 dilution) which had been incubated with the AML antigen, absorbed normal cell membrane antigen or PBS prior to labeling and analysis. A total of 25,000 cells was analysed in each case Figure 3 2D gel of 125I-labelled AML band 1. Two Mg of radiolabelled AML antigenic material (Greenwood et al., 1963) was focussed, electrophoresed and stained, as described in Figure 2 . Following drying the gel was autoradiographed for 18h at -70°C using Kodak X-Omat R film and Dupont Cronex Lightning-Plus X-ray intensifying screens. Mol. wt standards as indicated.
R. SHIPMAN-et al. In conclusion, our preliminary characterization of an antigen, which appears to be exclusively present on or in cells of patients with myloproliferative disorders, has shown the following. The same antigen as defined by a band seen on SDS-PAGE of absorbed membrane extracts, appears to be present in all AML cell extracts tested but was not found in equivalent preparations from cells from normal individuals or patients with lymphoproliferative disorders. This putative AML antigen, when eluted from preparative SDS-gels was found to be homogeneous in 2D gels and has been assigned a mol. wt of 68K daltons, and a pl of between 7.1 and 7.2. Finally, we have shown that this antigen can inhibit the reaction of a rabbit antiserum (prepared earlier in this laboratory) to bind to the surface of the HL-60 cell line, establishing that the AML antigen characterized here represents a surface marker on this cell line, and probably on cells of AML patients.
